Business
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program
About this update from Celldex Therapeutics, Inc.
[{"type":"image","alt":"Celldex Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Celldex Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":124,"url":"https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TpOULqxD5vaZLQ0RK_Jt6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979","width":300,"height":124}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline data expected Q4 2026","length":29,"tagName":"p"}]},{"val":[{"type":"text","content":"BLA submission planned for 2027","length":31,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":172,"olType":false},{"type":"text","content":"HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. The studies included 43 countries and over 500 sites.","length":493,"tagName":"p"},{"type":"text","content":"“Completing enrollment in these large Phase 3 CSU studies 6 months ahead of guidance highlights the significant unmet need in CSU and speaks to the excitement from patients and physicians about barzolvolimab and its potential as a best-in-disease treatment,” said Anthony S. Marucci, Co-founder, President and Chief Executive Officer of Celldex. “We are extremely grateful to these patients, their families and their treating physicians for their enthusiasm and participation in the EMBARQ-CSU1 and EMBARQ-CSU2 studies. We look forward to reporting topline results later this year and remain focused on completing preparations to support bringing this much needed treatment to more than 1.8 million patients in the United States suffering from CSU.”","length":749,"tagName":"p"},{"type":"text","content":"Barzolvolimab u...